[A case of paclitaxel and trastuzumab-resistant recurrent breast cancer with liver metastasis responding to S-1].

Abstract

We experienced a case of paclitaxel- and trastuzumab-resistant recurrent breast cancer with liver metastases showing significant improvement by S-1. A 76-year-old woman was diagnosed with left breast cancer (T2N1M0, Stage II B). She received total mastectomy and CEF (cyclophosphamide 500 mg/m(2), epirubicin 60 mg/m(2), 5-FU 750 mg/m(2)) as adjuvant chemotherapy in March 2004. But twelve months later, she was referred to our clinic for management of lung and left supraclavicular lymph node metastases. Then weekly paclitaxel (80 mg/m(2)) and trastuzumab were started. After 2 cycles of weekly paclitaxel and trastuzumab treatment, lung and lymph node metastases were reduced and the patient showed a clinical response (CR), so she was treated by trastuzumab only. But seven months later, she was diagnosed as a recurrence of liver metastases. She was treated by combined paclitaxel and trastuzumab again, but liver metastases and tumor marker were progressive. S-1 was administered orally 100 mg/day every day for 4 weeks, followed by a 2-week rest interval as 1 cycle, and trastuzumab was injected at 2 mg/kg/week for every weeks. After 2 courses of the treatment, the level of tumor marker and tumor size of liver metastases were reduced. Only rash (grade 1) was observed during treatment. The treatment of S-1 is thought to be effective for taxane-resistant recurrent breast cancer.

• Authors: Tsunehisa Nomura, Hiroshi Sonoo, Akiko Miyake, Mai Souda, Yutaka Yamamoto, Shigeo Shiiki, Masahiko Ikeda, Kazutaka Nakashima, Katsuhiro Tanaka, Junichi Kurebayashi
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 35 Issue 9 Pg. 1607-10 (Sep 2008) ISSN: 0385-0684 [Print] Japan
• PMID: 18799922 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Biomarkers, Tumor
• Trastuzumab
• Paclitaxel

Topics

• Aged
• Antibodies, Monoclonal (immunology, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Biomarkers, Tumor (blood)
• Breast Neoplasms (blood, drug therapy, immunology, pathology)
• Drug Resistance, Multiple (drug effects)
• Drug Resistance, Neoplasm (drug effects)
• Female
• Humans
• Immunotherapy
• Liver Neoplasms (blood, diagnostic imaging, drug therapy, secondary)
• Neoplasm Recurrence, Local (blood, diagnostic imaging, drug therapy, pathology)
• Neoplasm Staging
• Paclitaxel (therapeutic use)
• Tomography, X-Ray Computed
• Trastuzumab
• Treatment Failure